<DOC>
	<DOCNO>NCT02337205</DOCNO>
	<brief_summary>This phase 1 study access safety tolerability KX2-391 ointment subject Actinic Keratosis . This study also access amount KX2-391 drug enters blood stream dermal application ointment .</brief_summary>
	<brief_title>Ph 1 , Single-Center , Safety , Tolerability &amp; Pharmacokinetic Study KX2 391 Ointment Subj . w Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . Subject least 18 year old 2 . Subject clinical diagnosis stable , clinically typical AK 3 . Subject treatment area 1 dorsal forearm : Cohort 1 : Is one contiguous area Measures 25 cm2 Contains 4 8 AK lesion clinically typical . Cohort 2 : Is one contiguous area Measures 100 cm2 Contains 8 16 AK lesion clinically typical . 4 . All woman childbearing potential ( WOCBP ) must : Postmenopausal , define least 50 year age amenorrhea least 18 month , Surgically sterile , define undergone hysterectomy , bilateral oophorectomy tubal ligation , otherwise incapable pregnancy . Pre perimenopausal practice highly effective method birth control , include hormonal prescription , oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , duration participation study . Abstinence doublebarrier method qualify highly effective method birth control . All woman childbearing potential must negative serum pregnancy test screen negative urine pregnancy test Day 1 ( Visit 2 ) prior administration KX2391 Ointment dose . Contraception Contraception must consistently use least 3 month prior screen 3 month last KX2391 Ointment dose . Male Contraception : All men sexually active female partner child bear potential must agree ensure partner use highly effective contraception therefore father child screen 3 month last dose study medication . Male Female Contraception : All men woman subject must agree donate sperm egg attempt conception screen 3 month last KX2391 Ointment dose . 5 . Subject , opinion investigator , good general health base medical history , physical examination , electrocardiogram ( ECG ) , clinical laboratory evaluation screen . 6 . Subject clinically acceptable liver function screen demonstrate : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2x upper limit normal ( ULN ) Total bilirubin ≤ ULN 7 . No screen laboratory test , include CBC result , consider clinically significant investigator 8 . Subject lactate 9 . Subject willing able follow study instruction attend study visit 10 . Subject able comprehend willing sign Informed Consent Form ( ICF ) 1 . Subject clinically atypical and/or rapidly change AK lesion treatment area 2 . Subject current systemic malignancy 3 . Subject use follow systemic therapy within specific period Visit 1 : Retinoids ; 180 day Glucocorticosteroids ; 28 day Methotrexate antimetabolites ; 28 day 4 . Subject use follow topical therapy treatment area within specified period Visit 1 : Retinoids ; 90 day Glucocorticosteroids ; 14 day 5 . Subject follow AK therapy treatment area : Medical Therapies within 90 day ( site heal , whichever long ) Visit 1 : Ingenol mebutate ( eg , Picato ) 5fluorouracil ( eg , 5FU ; Efudex ) Imiquimod ( eg , Aldara ; Zyclara ) Diclofenac without hyaluronic acid ( eg , Solaraze ) Moisturizer , emollient ( 12 hour prior Visit 1 ) Surgical Modalities treatment area within 30 day ( site heal following treatment , whichever long ) Visit 1 : Cryotherapy Electrodesiccation Laser , light ( eg , photodynamic therapy , intense pulse light ) energy base therapy Chemical peel ( eg , tricholoracetic acid ) Dermabrasion Surgical removal ( eg , curettage , excision ) 6 . Subject currently , experience follow treatment area within specified period Visit 1 : A cutaneous malignancy ; 180 day Sunburn ; 28 day Body art ( eg , tattoo , pierce ) ; currently Excessive tan ; currently 7 . Subject history sensitivity ingredient study medication 8 . Subject chronically take know strong inhibitor CYP3A4 9 . Subject skin disease ( eg , atopic dermatitis , psoriasis , eczema ) condition ( eg , scar , open wound ) , opinion investigator , might interfere study conduct evaluation , expose subject unacceptable risk study participation . 10 . Subject significant uncontrolled unstable medical disease condition , opinion investigator , would expose patient unacceptable risk study participation . 11 . Subject participate investigational drug trial investigational study medication administer within 30 day Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>